Quarterly ResultMay 7, 2026, 04:35 PM
Amphastar Q1 GAAP EPS $0.14, Net Income $6.4M; Revenues Flat
AI Summary
Amphastar Pharmaceuticals reported Q1 2026 financial results with net revenues of $171.2 million, largely flat year-over-year. GAAP net income significantly decreased to $6.4 million ($0.14 per diluted share) from $25.3 million in Q1 2025. Adjusted non-GAAP net income also fell to $19.5 million ($0.42 per diluted share). The company highlighted the launch of Ipratropium Bromide HFA and a new licensing agreement for a synthetic corticotropin compound, alongside pipeline advancements.
Key Highlights
- Net revenues were $171.2 million for Q1 2026, a slight increase from $170.5 million in Q1 2025.
- GAAP net income decreased to $6.4 million ($0.14 diluted EPS) from $25.3 million ($0.51 diluted EPS) year-over-year.
- Adjusted non-GAAP net income was $19.5 million ($0.42 diluted EPS), down from $36.9 million ($0.74 diluted EPS).
- Gross profit declined 18% to $70.3 million, with gross margin at 41.1% compared to 50.0% in Q1 2025.
- R&D expenses increased 33% to $26.7 million, including a $2.0 million upfront licensing payment.
- BAQSIMI® sales decreased 15% to $32.4 million, while Glucagon sales fell 56% to $9.2 million.
- Other pharmaceutical product sales increased 34% to $67.1 million, driven by new launches.
- Company launched Ipratropium Bromide HFA and entered an exclusive license for a synthetic corticotropin compound.